You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 20, 2025

Investigational Drug Information for Gedatolisib


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug Gedatolisib?

Gedatolisib is an investigational drug.

There have been 12 clinical trials for Gedatolisib. The most recent clinical trial was a Phase 1 trial, which was initiated on September 30th 2022.

The most common disease conditions in clinical trials are Breast Neoplasms, Triple Negative Breast Neoplasms, and Pancreatic Neoplasms. The leading clinical trial sponsors are Pfizer, Celcuity, Inc., and Korean Cancer Study Group.

There are one hundred and eighteen US patents protecting this investigational drug and zero international patents.

Recent Clinical Trials for Gedatolisib
TitleSponsorPhase
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate CancerCelcuity IncPhase 1/Phase 2
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast CancerCelcuity, Inc.Phase 3
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)Celcuity, Inc.Phase 3

See all Gedatolisib clinical trials

Clinical Trial Summary for Gedatolisib

Top disease conditions for Gedatolisib
trials012345678Breast NeoplasmsTriple Negative Breast NeoplasmsPancreatic NeoplasmsProstatic Neoplasms, Castration-Resistant[disabled in preview]
Top clinical trial sponsors for Gedatolisib
trials01122334455667PfizerCelcuity, Inc.Korean Cancer Study Group[disabled in preview]

See all Gedatolisib clinical trials

US Patents for Gedatolisib

DrugnamePatent NumberPatent TitlePatent AssigneeEstimated Expiration
Gedatolisib ⤷  Subscribe Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity The University of North Carolina at Chapel Hill (Chapel Hill, NC) ⤷  Subscribe
Gedatolisib ⤷  Subscribe Low, immune enhancing, dose mtor inhibitors and uses thereof Novartis AG (Basel, CH) ⤷  Subscribe
Gedatolisib ⤷  Subscribe Triazine compounds as PI3 kinase and mTOR inhibitors Pfizer Inc. (New York, NY) ⤷  Subscribe
Gedatolisib ⤷  Subscribe Solid forms of (1S,4S)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-- trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide and methods of their use Signal Pharmaceuticals, LLC (San Diego, CA) ⤷  Subscribe
Gedatolisib ⤷  Subscribe Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids Cantex Pharmaceuticals, Inc. (Weston, FL) ⤷  Subscribe
>Drugname>Patent Number>Patent Title>Patent Assignee>Estimated Expiration
Showing 1 to 5 of 5 entries

International Patents for Gedatolisib

DrugnameCountryDocument NumberEstimated ExpirationRelated US Patent
Gedatolisib Australia AU2015244171 2034-04-11 ⤷  Subscribe
Gedatolisib Australia AU2015244179 2034-04-11 ⤷  Subscribe
Gedatolisib Canada CA2945128 2034-04-11 ⤷  Subscribe
Gedatolisib Canada CA2945129 2034-04-11 ⤷  Subscribe
Gedatolisib China CN106414451 2034-04-11 ⤷  Subscribe
>Drugname>Country>Document Number>Estimated Expiration>Related US Patent
Showing 1 to 5 of 5 entries

Gedatolisib: A Promising Drug Candidate in Oncology - Development Update and Market Projections

Introduction to Gedatolisib

Gedatolisib, developed by Celcuity Inc., is a small molecule drug candidate that has garnered significant attention for its potential in treating various types of cancer, particularly advanced breast cancer. Here, we delve into the recent development updates and market projections for this promising therapeutic agent.

Clinical Development Overview

Gedatolisib is currently under evaluation in multiple clinical trials for its efficacy and safety in several cancer types, including breast cancer, prostate cancer, and others.

Breast Cancer Trials

  • VIKTORIA-1 Trial: This ongoing Phase 3 trial is evaluating gedatolisib in combination with fulvestrant and a CDK4/6 inhibitor (either ribociclib or palbociclib) in patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer who have progressed on a prior first-line CDK4/6 inhibitor plus a non-steroidal aromatase inhibitor. Enrollment is expected to reach its target for the PIK3CA wild-type cohort in Q4 2024, with topline data anticipated between late Q4 2024 and Q1 2025[1][3][5].

  • VIKTORIA-2 Trial: Planned to initiate in Q2 2025, this Phase 3 study will assess the efficacy and safety of gedatolisib combined with fulvestrant and a CDK4/6 inhibitor as a first-line treatment for patients with HR+/HER2- advanced breast cancer. The trial will enroll approximately 638 patients across multiple sites globally[1].

Prostate Cancer Trials

  • Phase 1b/2 Trial: This trial is evaluating gedatolisib in combination with darolutamide for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). Preliminary data from this trial is expected in the first half of 2025, and the trial aims to enroll up to 54 patients[1][5].

Efficacy and Safety Data

Recent data presentations have highlighted the promising efficacy and safety profile of gedatolisib.

  • Median Overall Survival: A Phase 1b trial presented at the 2024 San Antonio Breast Cancer Symposium showed a median overall survival of 77.3 months in treatment-naïve patients and 33.9 months in patients previously treated with CDK4/6 inhibitors when gedatolisib was combined with palbociclib and endocrine therapy. These results are encouraging and compare favorably to current standard-of-care regimens[4].

  • Durable Responses: The addition of gedatolisib to palbociclib and letrozole has produced durable responses with comparable safety to that observed with palbociclib and letrozole alone in treatment-naïve patients with ER+/HER2- advanced breast cancer, as reported at the 2023 ESMO Breast Cancer Annual Congress[3].

Mechanism of Action

Gedatolisib acts by targeting the dual PI3K/mTOR pathways, which are crucial in cancer cell proliferation and survival. This triple pathway blockade strategy (ER, CDK4/6, and PAM signaling) represents an innovative approach that could potentially address resistance mechanisms common in breast cancer treatment[3][4].

Market Projections

Revenue Forecasts

According to GlobalData, the revenue for gedatolisib is expected to reach an annual total of $155 million by 2034 in the US. This forecast is based on the drug's phase transition success rate, remaining R&D costs, and the likelihood of approval and sales-related costs, all of which are factored into a risk-adjusted net present value (rNPV) model[2].

Commercial Potential

The strong survival data and efficacy results significantly enhance gedatolisib's commercial potential and Celcuity's market position. With a market capitalization of $474.9 million, Celcuity is well-positioned to leverage these positive clinical outcomes to drive market growth[4].

Funding and Financial Runway

Celcuity has secured a combined total of $129 million in gross proceeds from equity and debt financings, extending the company's cash runway for current clinical development program activities through 2026. This funding will support ongoing clinical programs, including the VIKTORIA-1 and VIKTORIA-2 trials, as well as the Phase 1b/2 trial for mCRPC[1][5].

Publications and Nonclinical Data

Several manuscripts reporting gedatolisib's clinical and nonclinical results have been published recently. These include findings in The Lancet Oncology, npj Breast Cancer, and Molecular Oncology, which highlight the drug's superior potency and efficacy compared to single-node PI3K/AKT/mTOR inhibitors in breast and prostate cancer models[5].

Expert Insights

"Gedatolisib's median OS results in combination with palbociclib and endocrine therapy are encouraging and compare favorably to published data for currently available first- or second-line standard-of-care regimens for patients with HR+/HER2- advanced breast cancer," said Igor Gorbatchevsky, MD, Chief Medical Officer of Celcuity. "These results highlight the promising clinical development strategy of simultaneously blocking the ER, CDK4/6, and PAM signaling pathways"[4].

Key Takeaways

  • Clinical Trials: Gedatolisib is being evaluated in multiple Phase 3 trials (VIKTORIA-1 and VIKTORIA-2) for HR+/HER2- advanced breast cancer and in a Phase 1b/2 trial for mCRPC.
  • Efficacy and Safety: The drug has shown promising efficacy and safety data, including durable responses and significant median overall survival rates.
  • Market Projections: Revenue forecasts indicate potential annual revenues of $155 million by 2034 in the US.
  • Funding: Celcuity has secured funding to extend its cash runway through 2026.
  • Mechanism of Action: Gedatolisib targets dual PI3K/mTOR pathways, offering a novel approach to addressing cancer resistance mechanisms.

FAQs

What is gedatolisib and how does it work?

Gedatolisib is a small molecule drug candidate that targets the dual PI3K/mTOR pathways, crucial in cancer cell proliferation and survival. It is being developed for various cancer types, including advanced breast cancer and metastatic castration-resistant prostate cancer.

What are the key clinical trials for gedatolisib?

The key clinical trials include the VIKTORIA-1 and VIKTORIA-2 Phase 3 trials for HR+/HER2- advanced breast cancer and a Phase 1b/2 trial for mCRPC.

What are the recent efficacy and safety findings for gedatolisib?

Recent data show a median overall survival of 77.3 months in treatment-naïve patients and 33.9 months in previously treated patients when combined with palbociclib and endocrine therapy. The drug has also produced durable responses with comparable safety to current standard-of-care regimens.

What are the market projections for gedatolisib?

Gedatolisib is expected to reach annual revenues of $155 million by 2034 in the US, based on a risk-adjusted net present value model.

How is Celcuity funded for the development of gedatolisib?

Celcuity has secured $129 million in gross proceeds from equity and debt financings, extending its cash runway through 2026 to support ongoing clinical programs.

What is the significance of the triple pathway blockade strategy of gedatolisib?

The triple pathway blockade strategy (ER, CDK4/6, and PAM signaling) represents an innovative approach that could potentially address resistance mechanisms common in breast cancer treatment, offering a new therapeutic option for patients.

Sources

  1. Celcuity Inc. Reports Second Quarter Financial Results and Provides Corporate Update. BioSpace, 2024.
  2. What is the current valuation of Celcuity's Gedatolisib? Pharmaceutical Technology, 2024.
  3. Gedatolisib Triplet Shows Early Efficacy in Previously Untreated ER+, HER2- Breast Cancer. OncLive, 2023.
  4. Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy. Stock Titan, 2024.
  5. Celcuity Inc. Announces Q2 Financial Results and Corporate Update. Synapse, 2024.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.